Etelcalcetide
FDA-approved IV (into a vein) calcimimetic (Parsabiv).
What it's for
Etelcalcetide is a lab-made peptide calcimimetic given intravenously after hemodialysis. It treats secondary hyperparathyroidism in adults with CKD (chronic kidney disease) on hemodialysis.
What it does for the body
It treats secondary hyperparathyroidism in adults with CKD (chronic kidney disease) on hemodialysis. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
It allosterically activates the calcium-sensing receptors (lock-and-key landing spots on cells) on parathyroid cells, lowering PTH (parathyroid hormone, which manages calcium) secretion. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Etelcalcetide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Bones research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Etelcalcetide — FDA.gov search
- ClinicalTrials.gov search: Etelcalcetide — U.S. clinical trials registry
- Drugs@FDA search: Etelcalcetide — FDA drug database (if approved)
- PubMed search: Etelcalcetide — NCBI PubMed
- PubMed Central search: Etelcalcetide — NCBI PMC